Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2026Scientific ReportsOpen Access

A novel glioma prognosis marker CAMK2A is related to immune microenvironment and may be involved in Ras/Raf/MEK/ERK signaling

View Full Paper
Ask AI
Bookmark
Share

Authors

ZSZhimin SunJZJiamin ZhangQJQianxu Jin

Discussion

Loading...

Member takes

Overview

Novel findings reveal CAMK2A's role in glioma prognosis, associating low expression with poor outcomes and immune interaction.

Key Points

  • To investigate the role of CAMK2A in glioma prognosis and its relationship with the immune microenvironment.
  • Analyzed CAMK2A gene expression through databases and validated by RT qPCR and Western blotting.
  • Conducted Kaplan-Meier survival analysis to correlate CAMK2A levels with glioma patient outcomes.
  • Performed enrichment analysis to identify biological functions related to CAMK2A expression.
  • CAMK2A expression significantly downregulated in glioma compared to normal tissue, decreasing with tumor grade.
  • Low CAMK2A expression linked to shorter overall survival (p-value not reported).
  • Overexpression of CAMK2A inhibited glioma cell proliferation, showing pathway regulation of Ras/Raf/MEK/ERK.

Cite This Study

Sun et al. (2026) studied this question.

synapsesocial.com/papers/6a3f6843aea7db3c1953f653https://doi.org/10.1038/s41598-026-57635-7
View Full Paper
Ask AI
Bookmark
Share